Edition:
United Kingdom

FUREN Group Pharmaceutical Co Ltd (600781.SS)

600781.SS on Shanghai Stock Exchange

13.58CNY
11 Dec 2018
Change (% chg)

¥0.13 (+0.97%)
Prev Close
¥13.45
Open
¥13.51
Day's High
¥13.66
Day's Low
¥13.31
Volume
6,214,782
Avg. Vol
3,202,361
52-wk High
¥23.35
52-wk Low
¥11.72

Latest Key Developments (Source: Significant Developments)

Furen Group Pharmaceutical Says 9-Month Net Profit Up 154.0 Percent Y/Y
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Furen Group Pharmaceutical Co Ltd <600781.SS>::SAYS 9-MONTH NET PROFIT UP 154.0 PERCENT Y/Y.  Full Article

Furen Pharmaceutical Group Industry to pay A shares div for FY 2017 on June 26
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Furen Pharmaceutical Group Industry Co Ltd <600781.SS> ::* Says it will pay cash dividend of 0.128 yuan(before tax)/A share for 2017 to shareholders of record on June 25.* The company's shares will be traded ex-right and ex-dividend on June 26 and the dividend will be paid on June 26.  Full Article

Furen Pharmaceutical Group Industry announces 2017 dividend payment
Monday, 23 Apr 2018 

April 23(Reuters) - Furen Pharmaceutical Group Industry Co Ltd <600781.SS>:Says it plans to pay cash dividend of 1.28 yuan per 10 shares (before tax) to the company's shareholders for 2017.  Full Article

Furen Pharmaceutical Group Industry acquires Kaifeng pharmaceutical firm via cash, share issue
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Furen Pharmaceutical Group Industry Co Ltd <600781.SS>:Says it acquired Kaifeng-based pharmaceutical firm via cash, share issue .  Full Article

Furen Pharmaceutical gets regulatory approval for asset acquisition
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Furen Pharmaceutical Group Industry Co Ltd <600781.SS>::SAYS IT GETS REGULATORY APPROVAL FOR ASSET ACQUISITION, SHARE TRADE TO RESUME ON NOV 30.  Full Article

China stocks end flat as drugmakers slump; up for the week

SHANGHAI, Dec 7 China's main equity market indexes ended flat on Friday in thin trade as investors remained cautious after the arrest of a senior Huawei executive sparked a global sell-off on fears it could derail hopes for a lasting U.S.-China trade detente.